The State Food and Drug Administration (SFDA) yesterday launched a special drive to intensify inspection on vaccine and blood products, reported the Beijing News Wednesday.

All vaccine and blood products are subject to sampling inspection and quality inspection before their delivery. Inspectors with SFDA will be dispatched to pharmaceutical workshops to carry out site inspections that will last till June.

According to the report, SFDA will revoke the Good Manufacturing Practice (GMP) authentication if the vaccine or blood products manufacturers' real situation is not in line with the procedure required by the authentication.

China introduced GMP authentication in 1998 to ensure medicine safety.

The Pharmaceutical Control Law stipulates that domestic pharmaceutical manufacturers must abide by international rules, laws, and practices. GMP is part of them.

In June 2005, a hepatitis A vaccine accident in Dazhuang town, Sixian county, East China's Anhui province, killed a four-year old girl and more than 300 students vaccinated were hospitalized.